Use of MULTIplex PCR, procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation: a trial controlled, randomized, open, in parallel groups, multicenter
Key facts
- Where
- Clermont Ferrand Cedex 1, JOSSIGNY, Lille, Lyon Cedex 03, Metz Cedex 03, Montpellier Cedex 5, Nice, Paris, Paris Cedex 20, Reims Cedex, Rouen Cedex és Saint-Mandé, FranciaországSee the 13 sites
- Phase
- 4. fázis
Where in Franciaország
- University Hospital Of Clermont-FerrandClermont Ferrand Cedex 1, FranciaországNo longer taking part
- Grand Hôpital de l'Est Francilien - Site de Marne la ValléeJOSSIGNY, FranciaországNo longer taking part
- CHRU de Lille - Hôpital SalengroLille, FranciaországNo longer taking part
- Hospital Edouard HerriotLyon Cedex 03, FranciaországNo longer taking part
- Centre Hospital Region Metz ThionvilleMetz Cedex 03, FranciaországNo longer taking part
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de NiceNice, FranciaországNo longer taking part
- Hôpital Bichat - Claude-BernardParis, FranciaországNo longer taking part
- Hôpital Saint-AntoineParis, FranciaországNo longer taking part
- Hopital TenonParis Cedex 20, FranciaországNo longer taking part
- Centre Hospitalier Universitaire ReimsReims Cedex, FranciaországNo longer taking part
- Centre Hospitalier Universitaire RouenRouen Cedex, FranciaországNo longer taking part
- Hôpital d'Instructions des Armées BéginSaint-Mandé, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique Hopitaux De Paris
- Trial code
- EU 2024-511896-13-00
- Record updated
- 2026. március 20.
- Original description
Evaluate the effectiveness in terms of antibiotic sparing of a personalized diagnostic and therapeutic strategy, compared to a usual strategy, during EA-COPD in the ICU/Rea.Read full original descriptionShow less
Use of MULTIplex PCR, procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation: a trial controlled, randomized, open, in parallel groups, multicenter (MULTI-EXA)
Evaluate the effectiveness in terms of antibiotic sparing of a personalized diagnostic and therapeutic strategy, compared to a usual strategy, during EA-COPD in the ICU/Rea.
Inclusion: Age ≥ 18 years old; Post-smoking COPD confirmed according to GOLD 2020, whatever the stage (I-IV); Acute exacerbation (defined by the appearance or increase of one or more of the usual signs/symptoms of COPD) with acute respiratory failure requiring admission to the ICU/Resuscitation and mechanical ventilation (invasive or non-invasive or nasal oxygen therapy high flow rate with FiO2 ≥ 50%); Consent (patient, relative or inclusion in emergency situation); Affiliation to a social security scheme.
Exclusion: Antibiotic therapy formally indicated for a suspected or documented extra-respiratory infection; Congenital or acquired immunosuppression (congenital immune deficiency, progressive high-grade hematological malignancy, immunosuppressive drugs in the last 30 days including cytotoxic anti-cancer chemotherapy and anti-rejection drugs, corticosteroid therapy ≥ 20 mg/d of prednisone equivalent for at least 14 days, neutropenia, HIV with unknown or known CD4<200/µL in the last 6 months); Delay between admission to hospital and admission to ICU/ICU greater than 3 days; Current pregnancy; Tracheotomy; Bronchial dilatation/cystic fibrosis; Moribund patient (imminent death); Patient deprived of liberty and/or protected by law; Patient already included in MULTI-EXA; Patient already included in a type 1 interventional clinical study (RIPH1) relating to antibiotics.